stdei glp-1 oral weight loss solution Analogues (Semaglutide) stdei glp-1
Description
Orforglipron (LY3502970) is a non-peptide GLP-1R agonist currently in clinical development that has demonstrated promising effects on glycemic control and body weight reduction, highlighting the continued expansion of GLP-1-based therapeutic strategies [4]
Authorization outcomes
Prescribing data reflect clinician intent but do not confirm whether prescriptions were filled
The lipotoxicity of FFA contributed to the downregulation of hepatic GLP-1R, which led to hepatic unresponsiveness to GLP-1 and disease progression
Leibowitz et al., 1981
[Article] [PubMed] [PMC]55
